Compare Incyte Corporation (INCY) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Southern Copper Corp — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Southern Copper Corp trades at $209.14 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 7.3× Incyte Corporation's market cap, and Southern Copper Corp pays a 2.21% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Southern Copper Corp for 61 Days on average.
| INCY | SCCO | |
|---|---|---|
Market Cap | $22.85B | $167.74B |
Volume | 1,927,029 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $219.70 |
52-Week Low | $83.80 | $120.02 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $18.35B | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.
SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
